# DiscGenics

> DiscGenics, Inc. is a privately held, late-stage clinical biopharmaceutical company
> headquartered in Salt Lake City, Utah, developing allogeneic, cell-based regenerative
> biologic therapies for degenerative diseases of the spine. Its lead candidate, IDCT
> (rebonuputemcel), is a single-injection allogeneic discogenic progenitor cell therapy for
> symptomatic mild-to-moderate lumbar degenerative disc disease, manufactured under cGMP from
> donated adult human intervertebral disc tissue and granted FDA Regenerative Medicine Advanced
> Therapy (RMAT) and Fast Track designations. DiscGenics is a therapeutics developer and
> publishes no public API, SDK, developer portal or machine-readable specification. This file
> was generated by API Evangelist from publicly reachable pages; it is not published by the
> company.

## Company

- [Home](https://www.discgenics.com/): Company overview and the discogenic cell therapy thesis.
- [Our Company](https://www.discgenics.com/about-us): About, mission, quality policy, leadership and careers.
- [Our Focus](https://www.discgenics.com/our-focus): Low back pain and the cell therapy approach.
- [Research & Development](https://www.discgenics.com/research-and-development): Discogenic Cells, IDCT, product pipeline, intellectual property and scientific publications.
- [Patients & Families](https://www.discgenics.com/patients-and-families): Degenerative disc disease, clinical trials and the expanded access policy.
- [Contact](https://www.discgenics.com/contact): General company contact.

## Clinical

- [DDDtrial.com](https://www.dddtrial.com/): Patient-facing recruitment site for the Phase III lumbar degenerative disc disease program, launched April 2026.
- [NCT07254806](https://clinicaltrials.gov/study/NCT07254806): Phase III study of IDCT (intradiscal cell therapy) — RECRUITING.
- [NCT03347708](https://clinicaltrials.gov/study/NCT03347708): Phase I/II safety and preliminary efficacy study of IDCT — COMPLETED.
- [NCT03955315](https://clinicaltrials.gov/study/NCT03955315): Japanese clinical study of IDCT — COMPLETED.

## News and media

- [Press Releases](https://www.discgenics.com/news): Company announcements.
- [Investors & Media](https://www.discgenics.com/investors-and-media): Events, presentations and investor material.
- [In the News](https://www.discgenics.com/in-the-news): Press coverage.
- [CEO's Blog](https://www.discgenics.com/ceos-blog): Long-form commentary from company leadership.
- [Japanese-language site](https://www.discgenics.com/home-ja): Full Japanese mirror of the company site, reflecting the PMDA-approved Japanese clinical program.

## Legal

- [Privacy Policy](https://www.discgenics.com/privacy-policy)
- [Terms of Use](https://www.discgenics.com/terms-of-use)

## Developer surface

There is none. As of 2026-08-12 the following were probed on www.discgenics.com and
www.dddtrial.com and all returned 404: /openapi.json, /openapi.yaml, /swagger.json,
/v1/openapi.json, /api-docs, /docs, /redoc, /graphql, /llms.txt, /.well-known/security.txt,
/.well-known/openid-configuration, /.well-known/oauth-authorization-server,
/.well-known/api-catalog, /.well-known/ai-plugin.json, /.well-known/agent-card.json and
/.well-known/agent.json. No OpenAPI, AsyncAPI, GraphQL SDL, MCP server, A2A agent card, SDK or
package-registry client library exists. Both sites are Squarespace-hosted marketing properties;
the `/api/` path disallowed in robots.txt is the Squarespace CMS internal path, not a public
API. A GitHub search returns zero users and zero repositories for "discgenics" — the company
operates no public GitHub organization.

The only machine-readable data about DiscGenics that a public agent can retrieve is
third-party: the ClinicalTrials.gov API (`https://clinicaltrials.gov/api/v2/studies?query.spons=DiscGenics`),
which serves the company's registered trial records as JSON. That is a US National Library of
Medicine surface, not a DiscGenics one.

## About this file

- [API Evangelist profile](https://apis.io/provider/discgenics/)
- Generated: 2026-08-12 | Method: generated | Source: apis.yml + probed public pages